160 related articles for article (PubMed ID: 19731022)
1. Statin therapy and serum transaminases among a cohort of HCV-infected veterans.
Henderson LM; Patel S; Giordano TP; Green L; El-Serag HB
Dig Dis Sci; 2010 Jan; 55(1):190-5. PubMed ID: 19731022
[TBL] [Abstract][Full Text] [Related]
2. Incidence of statin hepatotoxicity in patients with hepatitis C.
Khorashadi S; Hasson NK; Cheung RC
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):902-7; quiz 806. PubMed ID: 16697272
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.
Segarra-Newnham M; Parra D; Martin-Cooper EM
Pharmacotherapy; 2007 Jun; 27(6):845-51. PubMed ID: 17542767
[TBL] [Abstract][Full Text] [Related]
4. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
Chalasani N; Aljadhey H; Kesterson J; Murray MD; Hall SD
Gastroenterology; 2004 May; 126(5):1287-92. PubMed ID: 15131789
[TBL] [Abstract][Full Text] [Related]
5. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.
Kim HS; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Kim SH; Choi IY; Yoon KH; Kim JH
J Clin Pharm Ther; 2016 Jun; 41(3):266-72. PubMed ID: 27015878
[TBL] [Abstract][Full Text] [Related]
6. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.
Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B;
J Hepatol; 2014 Jan; 60(1):46-53. PubMed ID: 23978720
[TBL] [Abstract][Full Text] [Related]
7. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
[TBL] [Abstract][Full Text] [Related]
8. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
Mohanty A; Tate JP; Garcia-Tsao G
Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
[TBL] [Abstract][Full Text] [Related]
9. Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study.
Clement ME; Park LP; Navar AM; Okeke NL; Pencina MJ; Douglas PS; Naggie S
Clin Infect Dis; 2016 Aug; 63(3):407-13. PubMed ID: 27143663
[TBL] [Abstract][Full Text] [Related]
10. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.
Zuckerman E; Zuckerman T; Douer D; Qian D; Levine AM
Cancer; 1998 Sep; 83(6):1224-30. PubMed ID: 9740089
[TBL] [Abstract][Full Text] [Related]
11. Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Am J Cardiovasc Drugs; 2021 Jan; 21(1):103-112. PubMed ID: 32239436
[TBL] [Abstract][Full Text] [Related]
12. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.
Smith CC; Bernstein LI; Davis RB; Rind DM; Shmerling RH
Arch Intern Med; 2003 Mar; 163(6):688-92. PubMed ID: 12639201
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
Pandya P; Rzouq F; Oni O
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):555-65. PubMed ID: 25835493
[TBL] [Abstract][Full Text] [Related]
14. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
15. Adenosine deaminase activity in serum of patients with hepatitis -- a useful tool in monitoring clinical status.
Kaya S; Cetin ES; Aridogan BC; Arikan S; Demirci M
J Microbiol Immunol Infect; 2007 Aug; 40(4):288-92. PubMed ID: 17712462
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.
Fabrizi F; Lunghi G; Finazzi S; Colucci P; Pagano A; Ponticelli C; Locatelli F
Am J Kidney Dis; 2001 Nov; 38(5):1009-15. PubMed ID: 11684554
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia.
Desai NK; Mendelson MM; Baker A; Ryan HH; Griggs S; Boghani M; Yellen E; Buckley L; Gillman MW; Zachariah JP; Graham D; Jonas MM; de Ferranti SD
J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):175-181. PubMed ID: 30334928
[TBL] [Abstract][Full Text] [Related]
18. Monitoring statin safety in primary care.
Tragni E; Filippi A; Mazzaglia G; Sessa E; Cricelli C; Catapano AL
Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):652-7. PubMed ID: 17300133
[TBL] [Abstract][Full Text] [Related]
19. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.
Pastori D; Pani A; Di Rocco A; Menichelli D; Gazzaniga G; Farcomeni A; D'Erasmo L; Angelico F; Del Ben M; Baratta F
Br J Clin Pharmacol; 2022 Feb; 88(2):441-451. PubMed ID: 34133035
[TBL] [Abstract][Full Text] [Related]
20. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
Tzefos M; Olin JL
J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
